Tejas Savant
Stock Analyst at Morgan Stanley
(2.47)
# 2,489
Out of 5,050 analysts
234
Total ratings
46.62%
Success rate
-0.65%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Maintains: Overweight | $560 → $656 | $572.41 | +14.60% | 15 | Oct 28, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $65 → $68 | $71.56 | -4.97% | 4 | Aug 12, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $18 → $17 | $15.25 | +11.48% | 15 | Aug 12, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $100 → $105 | $121.90 | -13.86% | 9 | Aug 4, 2025 | |
| AVTR Avantor | Maintains: Equal-Weight | $15 → $12 | $11.55 | +3.90% | 20 | Aug 4, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $65 → $69 | $74.10 | -6.88% | 10 | Jul 31, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $10 → $8 | $10.08 | -20.63% | 14 | Jul 30, 2025 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $4.62 | +51.52% | 9 | May 28, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $8.38 | -16.47% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $14.79 | -39.15% | 12 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.87 | +74.22% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $79.40 | -74.81% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $199.57 | -7.30% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $210.46 | +18.79% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $24.10 | -4.56% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $41.70 | -32.85% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $6.30 | +233.33% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.76 | +13.64% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $8.95 | +346.93% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $1.51 | +297.35% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.37 | +128.83% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.10 | -11.29% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $6.93 | -27.85% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.09 | +378.47% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $96.72 | -24.52% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $168.05 | +48.77% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $7.73 | +1,193.66% | 5 | May 12, 2022 |
Thermo Fisher Scientific
Oct 28, 2025
Maintains: Overweight
Price Target: $560 → $656
Current: $572.41
Upside: +14.60%
Tempus AI
Aug 12, 2025
Maintains: Overweight
Price Target: $65 → $68
Current: $71.56
Upside: -4.97%
10x Genomics
Aug 12, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $15.25
Upside: +11.48%
Illumina
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $121.90
Upside: -13.86%
Avantor
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $11.55
Upside: +3.90%
Hologic
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $65 → $69
Current: $74.10
Upside: -6.88%
NeoGenomics
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $10.08
Upside: -20.63%
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.62
Upside: +51.52%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $8.38
Upside: -16.47%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $14.79
Upside: -39.15%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.87
Upside: +74.22%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $79.40
Upside: -74.81%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $199.57
Upside: -7.30%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $210.46
Upside: +18.79%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $24.10
Upside: -4.56%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $41.70
Upside: -32.85%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $6.30
Upside: +233.33%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.76
Upside: +13.64%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $8.95
Upside: +346.93%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $1.51
Upside: +297.35%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.37
Upside: +128.83%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.10
Upside: -11.29%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $6.93
Upside: -27.85%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.09
Upside: +378.47%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $96.72
Upside: -24.52%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $168.05
Upside: +48.77%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $7.73
Upside: +1,193.66%